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ABSTRACT 
Diabetes mellitus is a global health problem, owing to the high prevalence and 
enormous associated economic burden. Insulin resistance is a critical condition to the 
development of type 2 diabetes (T2D). Adiponectin, a hormone secreted by the adipose 
cells, has attracted much attention for its insulin-sensitizing and anti-diabetic effects.  
 
The overall aim of this thesis was to have a better understanding of the roles of 
ethnicity, genetic variants and dietary factors in relation to adiponectin and insulin 
resistance by means of different analytical approaches.   
 
In Study I, using path analysis, we examined potential mediators including body 
fatness, adiponectin levels, and inflammation for the extent they mediate the ethnic 
differences in insulin resistance among Singaporean Chinese, Malays and Indians. 
General adiposity explained the difference in insulin resistance between Chinese and 
Malays, whereas abdominal fat distribution, inflammation, and unexplained factors 
contributed to excess insulin resistance in Asian Indians as compared with Chinese and 
Malays. 
 
In Study II, we carried out a genome-wide association study to identify genetic variants 
that influence adiponectin levels in East Asian populations. The top signal from 
CDH13 explains a substantial part of variation in high-molecular-weight (HMW) 
adiponectin levels, but its effect on circulating HMW adiponectin levels did not appear 
to translate into effects on insulin-resistance related metabolic traits, suggesting that 
compensatory mechanisms exist that lead to greater ‘adiponectin sensitivity’. 
 
In Study III, the question whether changes in adiponectin levels causally influence 
insulin sensitivity was addressed by a Mendelian randomization design in a cohort of 
Swedish men. Genetically determined adiponectin levels influence euglycemic clamp-
measured insulin sensitivity to the same degree as the observed epidemiological 
associations. Thus, the observed association between higher adiponectin levels and 
increased insulin sensitivity is likely to represent a causal relationship. 
 
In Study IV, we examined relations between serum selenium levels and measures of 
glucose and insulin metabolism, as well as risk of T2D longitudinally in Swedish men. 
There was no clear evidence of an effect of selenium status on various measures of 
insulin sensitivity or β-cell function. Selenium levels were also not associated with risk 
of T2D. These results do not support a role for selenium supplementation as a broad 
approach for the prevention of T2D. 
 
In conclusion, mediators of ethnic differences in insulin resistance differed markedly in 
the Singaporean populations. In East Asians, CDH13 strongly influences adiponectin 
levels and associates with a beneficial metabolic profile when controlling for 
circulating adiponectin. Inferred from genetics, the positive relationship between 
adiponectin and insulin sensitivity appears to be causal. There is no evidence of an 
effect of selenium intake on glucose and insulin metabolism or risk of T2D in the 
Swedish population.   
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1 BACKGROUND 
 
1.1 Diabetes 
1.1.1 Prevalence of diabetes 
Diabetes mellitus is one of the most common non-communicable diseases in the world 
nowadays. It has three major types, namely type 1 diabetes, type 2 diabetes (T2D) and 
gestational diabetes. T2D used to be called non-insulin dependent diabetes and 
accounts for at least 90 percent of all diabetic cases. The global prevalence of diabetes 
by International Diabetes Federation (IDF) was estimated to be 8.3% in 2011 and this 
number is projected to reach 9.9% with a burden of 438 million individuals in 2030 [1].  
The economic cost incurred is heavy and 471 billion USD were spent due to diabetes in 
2012 [1], not to mention the indirect and intangible costs. 
 
A remarkable feature is that developing countries now experience more serious 
situation than developed countries, as 4 out of 5 people with diabetes live in low- and 
middle-income countries. In addition, almost half of the global burden of diabetes now 
falls in Asia, mainly due to large population size in China and India. The estimated 
number for 2011 was reported to be 92.4 million in China [2] and 62.4 million in India 
[3].  
 
Moreover, T2D is often undiagnosed and according to the IDF statistics, 50% of the 
people were unaware of their condition. Patients are usually only diagnosed due to 
serious macrovascular and microvascular complications which include cardiovascular 
diseases, kidney failure (diabetic nephropathy), neurological complications (diabetic 
neuropathy) and eye diseases (diabetic retinopathy).   
 
1.1.2 Pathophysiology of the disease 
T2D is a disorder in glucose metabolism characterized by hyperglycemia. It results 
from a combination of defects in insulin secretion and insulin action and is hallmarked 
by resistance to effects of insulin in the liver, skeletal muscle and adipose tissues. As a 
result, the pancreatic β-cells increase the release of insulin to compensate for the 
reduced insulin action, until β-cell dysfunction occurs when the high demand cannot be 
met.  
 
The relationship between β-cell function and insulin sensitivity is nonlinear following a 
hyperbolic shape and β-cells adapt to changes in insulin sensitivity by improved 
functional responsiveness and an increase in volume/mass [4, 5]. The degree of 
abnormality of insulin release by the β-cells proved to be the primary determinant of 
differences in glucose tolerance between individuals. Moreover, β-cell function 
declines progressively and the risk could be pre-existing, or genetically determined 
[4, 6].  
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The heritability of T2D is high according to twin studies and family studies [5]. 
However, known genetic variants explained only <10% of the estimated genetic 
contribution. Chronic over-nutrition and a failure to contain this fuel surfeit is the 
primary cause for the development of T2D [7]. Overweight and obesity are highly 
associated with risk of diabetes. However, many obese individuals manage to maintain 
normal glucose levels and do not develop diabetes in their entire life which implies the 
existence of interplay between genetics and environment. Moreover, early-life 
environment could regulate fatal and neonatal programming through epigenetic effects 
and hyperglycemic intrauterine environment is believed to contribute to the 
pathogenesis of T2D [8, 9].  
 
1.2 Insulin resistance 
1.2.1 Definition 
Insulin is secreted in the β-cells of the pancreatic islets of Langerhans in response to 
elevated blood glucose levels after a meal. The major tissues insulin targets to lower 
blood glucose levels include the liver, skeletal muscles and adipose tissue. Insulin 
suppresses gluconeogenesis in hepatic cells and promotes glucose uptake in the 
muscles and adipocytes. Insulin sensitivity measures the responsiveness of tissues to 
insulin action and conversely, insulin resistance refers to a condition where the body 
is less sensitive to the functions of insulin. As a result, high level of insulin is usually 
observed under insulin-resistant condition. 
 
1.2.2 Diagnostic tests 
The gold-standard method to measure insulin sensitivity is the glucose clamp, or 
more specifically, the hyperinsulinemic euglycemic clamp [10]. As the name suggests, 
in this test insulin is infused at a constant high rate to reach a hyperinsulinemic status. 
This stimulates glucose uptake in skeletal muscles and adipose tissue and suppressed 
glucose production in the liver. Glucose is infused during the entire process in order 
to keep glucose concentration at constant levels. At steady-state the glucose infusion 
rate is assumed to equal glucose disposal rate which measures tissue sensitivity to 
exogenous hyper insulin levels. However, this test requires sophisticated equipment 
and is time-consuming and labor-intensive, and is thus rarely used in large 
epidemiological studies. 
 
There are indirect measures of insulin sensitivity based on dynamic tests. One of such 
is the intravenous glucose tolerance test (IVGTT) and the most widely used method is 
the minimal model analysis of frequently sampled intravenous glucose tolerance test 
(FSIGT) [11]. FSIGT involves frequent blood samples for the measurement of 
glucose and insulin concentrations, and is slightly less laborious than the clamp 
method. There are also measures that are based on the oral glucose tolerance test 
(OGTT), a test widely used in clinical settings. Some OGTT-derived indices for the 
assessment of insulin sensitivity include the Matsuda index [12], the Stumvoll index 
[13], the Gutt index [14] and the Belfiore index [15].  
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In large epidemiological studies, it is common to use simple fasting measures of 
blood glucose and insulin concentrations to estimate insulin sensitivity and β-cell 
function. The Homeostasis model assessment index of insulin resistance (HOMA-IR) 
[16] uses simple equation to compute a surrogate index of insulin resistance based on 
steady-state basal glucose and insulin concentrations. However, it correlated more 
weakly with euglycemic clamp-measured insulin sensitivity, as compared with the 
OGTT-derived indices [17].  
 
1.2.3 The role of obesity in insulin resistance and T2D 
Mammalian adipose tissues consist of white and brown adipose. The brown fat is 
involved in thermogenesis and in human it is mainly found in newborn infants. 
Instead, the white adipose tissue has an important role in maintaining whole-body 
glucose homeostasis as well as lipid metabolism and adipocyte dysfunction is closely 
linked to insulin resistance and T2D.  
 
Since the discovery of leptin in 1994 [18], the adipose tissue is increasingly 
recognized for its function as an endocrine organ. The white adipose tissue secretes 
numerous cytokines and hormones collectively known as adipocytokines, or 
adipokines [19]. Most of them, such as tumor necrosis factor-α (TNF-α), interleukin-6 
(IL-6), leptin, retinol-binding protein 4 (RBP4) are pro-inflammatory, while 
adiponectin (introduced in the next chapter) has a unique anti-inflammatory and 
insulin sensitizing property [19-21]. This is important because chronic low-grade 
inflammation has been implicated in obesity and insulin resistance. C-reactive protein 
(CRP) is an acute-phase protein that serves as an important marker of systemic 
inflammation and is also related to insulin resistance [22]. 
 
Hypertrophic adipocytes increase secretion of many adipokines including monocyte 
chemoattractant protein-1 (MCP-1), also known as chemokine (C-C motif) ligand 2 
(CCL2). MCP-1/CCL2 recruits additional macrophages which secretes large amount 
of TNF-α, resulting in an inflammatory state [23]. Increased lipolysis and decreased 
triglyceride storage lead to higher circulating levels of non-esterified fatty acids 
(NEFAs) and triglycerides. This causes ectopic lipid accumulation and impairs 
insulin-stimulated glucose uptake in skeletal muscle, which is believed to be a 
primary cause of insulin resistance [24]. Similarly, excess fatty acids in the liver 
decrease the responsiveness of the hepatic cells to insulin.  
 
High levels of NEFAs may be the most critical determinant of insulin sensitivity. One 
proposed mechanism [25] is that increased intracellular concentrations of fatty acid 
metabolites, such as fatty acyl-coenzyme A (fatty acyl-CoA), diacylglycerol (DAG), 
and ceramides lead to phosphorylation of insulin receptor substrates (IRS) at 
serine/threonine site, and this disrupts the insulin signaling pathway by deactivating 
the phosphatidylinositol 3–kinase (PI 3-kinase). As a result, downstream insulin 
signaling and glucose transport is compromised.  
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Fat distribution is another important contributor of insulin resistance and abdominal 
obesity is closely associated with adverse metabolic consequences [26, 27]. Visceral 
adipose tissue is more lipolytic and less insulin-sensitive than the subcutaneous 
adipose tissue [28]. Together with the fact that the visceral fat depot is in closer 
proximity to the liver, portal NEFA levels are elevated in abdominal obesity. The 
expected results are increased hepatic glucose production and peripheral 
hyperglycemia [29].  
 
 
1.2.4 Ethnic differences 
Marked differences in insulin resistance exist between ethnic groups [30]. At the same 
degree of body fatness, whites have been consistently observed to have the lowest level 
of insulin resistance among major ethnic groups in the world [31-33].  
 
Focusing on Asia where the burden of T2D is the heaviest, Asians, and particularly 
Asian Indians, are more insulin resistant than whites for a given degree of adiposity 
[34]. For the same body mass index (BMI), Asian Indians tend to have a higher level of 
body fat than whites [35] and they were more insulin resistant than whites for the same 
level of total body fat [36, 37], likely contributed by their abdominal fat distribution 
[38-40], differences in adipocyte cell size [37] and a higher ratio of total body fat to 
lean mass [36]. In addition, lower adiponectin levels [30, 31, 33, 41-43], higher CRP 
levels [43-45] as compared with whites independent of BMI, and dietary factors may 
contribute to the higher susceptibility of Asian Indians in developing T2D [46, 47]. 
 
Several studies in the U.S. have also demonstrated greater insulin resistance in East 
Asians as compared with whites for a given BMI [32, 48, 49]. For example, Chinese-
American and Japanese-American women were more insulin resistant than white 
women after adjusting for waist circumference [48]. Asian Americans have also been 
shown to be more likely to develop T2D than whites after adjustment for BMI [50]. 
Lower adiponectin levels in East Asians than BMI-matched whites, as reported for 
Japanese men [51] and for Koreans men and women [52], may contribute to these 
ethnic differences in insulin resistance and T2D. In a Canadian study, Chinese had 
lower adiponectin levels than whites in both men and women after considering 
differences in waist circumference [30].  
 
There is also evidence for substantial differences in insulin resistance between ethnic 
groups in Asia. Asian Indians are more insulin resistant and glucose intolerant than 
Chinese and Malays [53], but reasons for these ethnic differences are not well 
understood. One of the major contributing factors could be adiposity and fat 
distribution, as Asian ethnic groups differ from each other in body composition [54]. 
However, this does not fully explain the ethnic difference in insulin resistance. In 
Singapore, for example, Malays have the highest levels of adiposity, but not the highest 
levels of insulin resistance [53]. Circulating adipokines and inflammatory markers may 
contribute to some of the differences in insulin resistance between Asian ethnic groups, 
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but to what extend these factors mediate the relation between ethnicity and insulin 
resistance independently and inter-connectively remains largely inconclusive.  
 
1.2.5 Dietary antioxidants 
Oxidative stress manifests an imbalance between the production of reactive oxygen 
species (ROS) and antioxidant defenses [55]. Increased ROS levels and excessive 
oxidative stress trigger insulin resistance, impair glucose tolerance and β-cell function, 
and accelerate the development of T2D [56-58]. Some of the most recognized dietary 
antioxidants include vitamin C, vitamin E, selenium and carotenoids.  
 
A meta-analysis showed that the intake of antioxidants was associated with 13% 
reduction in the risk of T2D and this was mainly attributed to vitamin E and 
carotenoids [59]. Several longitudinal studies have found that dietary β-carotene (a 
subtype of carotenoids) and α-tocopherol (a subtype of tocopherol, or vitamin E) 
independently predicted risk of T2D [60-62], possibly mediated by an improvement 
in insulin sensitivity [62]. However, supplementation of β-carotene and α-tocopherol 
in randomized clinical trials (RCTs) revealed no benefit in the prevention of T2D and 
indicated that the relationship may not be causal [59].  
 
Flavonoids are compounds with anti-oxidant capacities. A recent large prospective 
study found an association between consumption of foods rich in anthocyanin (a sub-
class of flavonoids), especially berries and apples/pears, and a lower risk of T2D[63].   
 
In contrast to anti-oxidants, excess iron is believed to elicit toxic effects mainly 
related to oxidative stress, due to the generation of ROS during a redox cycle [64]. 
High body iron store, as reflected by serum ferritin levels, has been associated with 
increased risk of T2D and it was suggested that dietary iron caused insulin resistance 
through down-regulation of adiponectin [65, 66].  
 
Selenium  
Selenium is an essential trace mineral. It exists predominantly as selenocysteine and 
selenomethionine in foods, but the content varies greatly depending on the soil 
conditions. Selenocysteine (Se-Cys) is a cysteine analogue with a selenium-
containing selenol group replacing the sulfur-containing thiol group. Proteins that 
include a selenocysteine amino acid are called selenoproteins. The most abundant 
selenoprotein in the plasma is selenoprotein P [67, 68]. Glutathione peroxidases (GPx) 
is a family of enzymes with peroxidase activity that detoxify peroxides and 
hydroperoxides. They are involved in antioxidant defense and protect against 
oxidative stress. GPx are also selenoproteins accounting for 10-30% of plasma 
selenium [67] and it contains selenium as selenocysteine in the catalytic site.   
 
Selenium has been suggested to have insulin-mimetic and anti-diabetic properties [69, 
70], but results from existing studies on its association with risk of T2D are 
inconclusive [70]. In cross-sectional studies, higher selenium status has been associated 
with both a lower and a higher prevalence of diabetes [71-73]. Most RCTs concluded 
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no overall efficacy of selenium supplementation on risk of diabetes and glucose control 
[74-76]. Importantly, selenium supplementation in clinical trials is usually given in 
high doses and effects may thus not reflect effects of smaller variation in dietary 
selenium intakes. To date, little evidence is available from prospective cohort studies of 
selenium status in relation to glucose tolerance and risk of diabetes. In addition, there is 
a lack of studies studying selenium intake in relation to detailed measures of insulin 
processing, secretion and sensitivity. 
 
Selenium content in foods varies greatly depending on soil conditions and as a result, 
selenium intakes calculated using food composition databases are inaccurate. In 
contrast, serum/plasma selenium is a reliable biomarker for selenium status [77, 78]. 
The correlation between serum selenium and selenium intake has been shown to be 
reasonably high [79]. Besides, erythrocyte selenium and toenail selenium are good 
measures of long-term selenium intake.  
 
1.3 Adiponectin 
1.3.1 Structure and circulating forms 
Adiponectin is a 30-kDa protein secreted by the adipocytes. It is the most abundant 
adipokine in the circulation and its levels remain relatively constant [80, 81]. The 
protein is composed of four domains: an N-terminal signal peptide, a variable region, a 
collagenous domain, and a C-terminal globular domain. Adiponectin exists in full-
length as multimer complexes, and also as a globular fragment. The three major 
oligomeric forms include the low-molecular-weight (LMW) trimer, the middle-
molecular-weight (MMW) hexamer and the high-molecular-weight (HMW) 12-18mer 
[82]. The different isoforms could have distinct properties and exert diverse biological 
functions, although this is not completely understood yet. Therefore, multimer 
distribution, in addition to total adiponectin concentration, should also be considered in 
the interpretation of adiponectin levels and health outcomes [83]. 
 
1.3.2 Receptors and signaling pathways 
Three adiponectin receptors are known to date. Adiponectin receptor 1 (AdipoR1) and 
adiponectin receptor 2 (AdipoR2) are transmembrane receptors having an inverse 
topology as compared with the G protein-coupled receptors [84]. A third receptor, T-
cadherin, belongs to the cadherin family of proteins and has not been well-
characterized for its function with adiponectin. It lacks an intracellular domain and is 
attached to the membrane by a glycosylphosphatidylinositol (GPI) anchor [85]. 
 
AdipoR1 binds to globular adiponectin with high affinity and AdipoR2 has 
intermediate affinity for both globular and full-length adiponectin [84]. Both receptors 
are abundantly expressed, although the relative abundance varies in tissues. T-cadherin 
is a receptor exclusively for hexameric and HMW adiponectin [85] and is expressed in 
the endothelial and smooth muscle cells [86].  
 
Adiponectin mainly signals through the adenosine monophosphate (AMP)-activated 
protein kinase (AMPK) and the peroxisome proliferator activated receptor-α (PPAR-α) 
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signaling pathways [87, 88]. However, individual isoforms seem to have different 
biological activities and activate different signal transduction pathways. In skeletal 
muscle, trimeric adiponectin activates AMPK, whereas the hexamer and HMW form 
activate NF-kB pathway [89]. In the liver, AMPK are stimulated by full-length 
adiponectin only [87]. Therefore, it is possible that adiponectin controls its ligand 
signaling by different oligomerization states. Without an intracellular domain, T-
cadherin is thought to have no role in signal transduction, although it is capable of 
binding adiponectin.  
  
 
1.3.3 Functions in glucose and fatty acid metabolism 
Although adiponectin is primarily produced by the adipose tissue, as a paradox, blood 
levels of adiponectin are inversely associated with obesity [90]. In addition, a sexual 
dimorphism is observed where adiponectin levels are higher in women than in men, but 
this is not explained by fat mass [91] and could be partially accounted for by the 
inhibitory effect from testosterone [92, 93].  
 
It is also well-established that adiponectin levels are inversely associated with degree of 
insulin resistance [94, 95] and lower adiponectin is also associated with higher risk of 
T2D [96]. In concordance, hypoadiponectinemia is observed in insulin resistance-
related conditions such as metabolic syndrome, hypertension, dyslipidemia, and 
oxidative stress [97]. However, it remains a question whether the inverse relationship 
between adiponectin levels and degree of insulin resistance represents a causal 
relationship. 
 
In the liver, adiponectin lowers glucose levels by suppressing gluconeogensis and 
sensitizes hepatic cells to the effects of insulin by a reduction in lipid content [21, 98]. 
This is achieved by the inhibition of the expression of gluconeogenic enzymes and the 
phosphorylation of acetyl coenzyme A carboxylase (ACC). In skeletal muscle, it 
activates AMPK, thereby stimulating phosphorylation of ACC, fatty acid oxidation and 
glucose uptake [87, 99]. In particular, HMW adiponectin has been suggested to be the 
bioactive form having stronger associations with insulin sensitivity and suppression of 
hepatic glucose production than other forms of adiponectin [83, 100-102].  
 
In obese or obese T2D individuals, activation of AMPK signaling and fatty acid 
oxidation by globular adiponectin is reduced, not due to the expression of adiponectin 
receptors, but as a result of downstream signaling after receptor binding [103]. APPL1, 
an adaptor protein, has been suggested to be a key molecule in signal transduction 
linking adiponectin receptors and AMPK activation [104].  
 
1.3.4 Heritability and genetic predisposition 
Genetic determinants account for a substantial proportion of the variation in plasma 
adiponectin, as estimated to be 30 -70% [105-107].  
 
Genome-wide scans based on LOD scores have identified signals on chromosome 5 
and 14 in Europeans [107], on chromosome 9 in Pima Indians [106], and on 
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chromosome 15 in East Asians [105]. The region flanking the adiponectin gene locus 
on chromosome 3 was first reported to be responsible for the linkage to adiponectin 
levels in an Amish population through an initial linkage scan plus fine-mapping using 
single nucleotide polymorphisms (SNPs) [108]. However, linkage studies had limited 
accuracy in the ascertainment of the exact genomic location harboring the signal and 
more importantly, very few linkage studies (for any traits) have been replicated - 
probably due to the power being too low in all such studies. 
 
With the advancement of the Genome-wide association studies (GWAS) era, a 
substantial larger number of adiponectin-associated loci have been identified using the 
SNPs as markers. These include the adiponectin gene ADIPOQ [109-112], CDH13 
which exhibited as a prominent signal in Asians [113-116], ARL15 [109] and FER 
[112]. A recent multi-ethnic large GWAS meta-analysis identified 10 novel loci and 
this increased the known loci to 14 in total. Many of the newly identified loci, such as 
IRS1, PEPD, GPR109A, and ZNF664, have functional relevance with insulin resistance 
and T2D [117].  
 
The ADIPOQ gene is located on chromosome 3q27 and consists of 3 exons spanning 
17kb. Many common polymorphisms in the promoter, exon and introns, as well as rare 
non-synonymous mutations have been associated with obesity, glucose and insulin 
metabolism and T2D in diverse populations [118]. Variants in the adiponectin receptor 
genes ADIPOR1 and ADIPOR2 have also been found to associate with insulin 
resistance and T2D, but not always replicated across populations. Potential reasons that 
limit the reproducibility include undetected population structure, false-positive results, 
small sample sizes, between-study heterogeneity, imprecise measurement of 
phenotypes and gene-environment interactions [119].  
 
Another gene highly associated with adiponectin levels is CDH13 on chromosome 16 
and it contains 14 exons and spans 1.2 Mb. This gene encodes for T-cadherin which 
binds hexameric and HMW adiponectin in the vasculature and endothelial cells [85].  
Despite the strong association of CDH13 with adiponectin, follow-up studies for its 
roles in metabolic disorders are lacking. Polymorphisms in the CDH13 gene are not 
broadly studied and the mechanisms of T-cadherin in adiponectin signaling and insulin 
resistance are unclear at the moment. 
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2 AIMS OF THE THESIS 
The overall aim of this thesis was to have a better understanding of the role of ethnicity, 
genetic variants and dietary factors as determinants of adiponectin levels and insulin 
resistance by means of different analytical approaches. The specific aims were: 
 
- To evaluate to what extent body fatness, adiponectin levels, C-reactive protein 
and their interconnections mediate the relation between ethnicity and insulin 
resistance by path analysis in an Asian context. (Study I) 
 
- To identify common genetic variants associated with adiponectin levels on a 
genome-wide scale and examine their associations with insulin resistance and 
related metabolic risk factors in East Asians. (Study II) 
 
- To elucidate the potential causal effect of adiponectin on insulin sensitivity 
measured by euglycemic insulin clamp in a cohort of Swedish men using a 
Mendelian randomization approach. (Study III) 
 
- To investigate prospectively the relationship between baseline selenium 
concentration as a surrogate of selenium dietary intake and measures of glucose 
metabolism and incidence of type 2 diabetes in Swedish men. (Study IV) 
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3 METHODS 
3.1 Participants 
3.1.1 The Singapore Prospective Study Programme (SP2) 
Participants of SP2 previously participated in cross-sectional studies carried out from 
1982 to 1998, namely the Thyroid and Heart Study (1982-1984) [53], the National 
Health Survey (1992) [120], the National University of Singapore Heart Study (1993-
1995) [53], and the National Health Survey (1998) [121]. Each of these studies was 
based on a random sample of Singapore residents with the minority groups (Malays and 
Asian Indians) being over-sampled. From 2003 to 2007, all 10,747 participants from 
these studies were invited to participate in the SP2 study. Of these, 559 had deceased at 
the time of study, 6 emigrated, and 102 were excluded because of errors in their 
identity card numbers. Qualified participants were contacted and 7,774 completed the 
questionnaire. The remainder was invited to a health screening which 5,164 subjects 
attended. Figure 1 is a flow-chart of the design of this study.  
 
 
Figure 1. Design of the Singapore Prospective Study Programme 
 
Written informed consent was obtained from all participants and ethics approval was 
obtained from the Singapore General Hospital and the National University Hospital 
Institutional Review Boards. 
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3.1.2 The Uppsala Longitudinal Study of Adult Men (ULSAM) 
The Uppsala Longitudinal Study of Adult Men (ULSAM) was initiated between 
September 1970 and September 1973 with an invitation of all 50-year-old men living in 
Uppsala County, Sweden. Of the invited, 82% participated in the investigation. There 
are five follow-ups to date, at 60, 70, 77, 82 and 88 years of age. Figure 2 is an 
overview of the design of this cohort study and detailed information can be found at the 
cohort website (http://www.pubcare.uu.se/ULSAM/). The main sample used for this 
thesis work comes from the third investigation during 1991-1995 when the subjects 
were approximately 71 years old. A total of 1,221 men (73% of those invited, i.e. men 
still alive and residing in Uppsala County) participated and the examination included a 
medical questionnaire, blood pressure and anthropometric measurements, collection of 
blood samples, a 75-gram oral glucose tolerance test, and insulin sensitivity 
measurements.  
Figure 2. Overall design of the Uppsala Longitudinal Study of Adult Men. 
 
The ULSAM study was approved by the Ethics Committee of Uppsala University, and 
all participants provided written informed consent. 
 
3.2 Measurements 
3.2.1 SP2 (Study I and II) 
Height was measured using a wall mounted measuring tape and weight was measured 
using a digital scale. Waist circumference was measured midway between the lower rib 
margin and the iliac crest and hip circumference was measured at the widest point over 
the greater trochanters. BMI was computed as weight (kg) divided by height square 
(m2). Demographic data including ethnicity and lifestyle information such as smoking 
status and alcohol intake were assessed using standardized questionnaires. Total 
physical activity was measured using a locally validated questionnaire covering activity 
in four domains (household, occupational, leisure-time and transport). 
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Fasting blood samples were analyzed for glucose using enzymatic methods (ADVIA 
2400, Siemens, Germany), for insulin using micro-particle enzyme immunoassay 
(Abbot AXSYM, Abbott Laboratories, Chicago, IL), for high-sensitivity CRP using an 
immuno-turbidimetric assay (Roche Diagnostics, Rotkreuz, Switzerland), and for total 
and HMW adiponectin using an enzyme linked immune-sorbent assay (Sekisui Medical 
Co Ltd, Japan). Insulin resistance was assessed by HOMA-IR calculated as: (fasting 
insulin in mIU/L x fasting glucose in mmol/L) / 22.5 [16]. The intra and inter batch 
coefficient of variations percent were as follows: glucose (2.5, 6.6), insulin (4.0, 4.5), 
total adiponectin (18.1, 15.9), HMW adiponectin (6.8, 18.3) and CRP (0.6–1.3, 2.3–
3.1).   
 
3.2.2 ULSAM (Study III and IV) 
At baseline (50 years old) 
An IVGTT was performed where blood glucose and serum insulin levels were 
measured between 0 and 60 min after the intravenous glucose load. Proinsulin 
concentrations were analyzed using the two-site immunometric assay technique [122]. 
Glucose tolerance was evaluated by the K-value calculated as K=ln2·100/T1/2 where 
T1/2 is the time in minutes required for the concentration to be reduced by half its value. 
Early serum insulin response was represented by the insulin peak and expressed as the 
mean value of the serum insulin concentrations determined at 4, 6 and 8 minutes. The 
insulin index was defined as the ratio between peak serum insulin response and fasting 
serum insulin concentration. Based on fasting glucose and insulin concentrations, the 
homeostasis model assessment index for insulin resistance and β-cell function (HOMA-
IR and HOMA-B) were calculated [16].  
 
T2D was ascertained by elevated fasting blood glucose (≥ 6.1 mmol/L, which equals 
plasma glucose ≥ 7.0 mmol/L) or use of anti-diabetic medicine. 
 
Selenium was determined in serum using the graphite-furnace atomic absorption 
spectrometric method [123]. Samples were diluted (1+9) with a solution containing 
nickel (to reduce the volatility of selenium) and nitric oxide (to keep samples free of 
precipitates) and measured by a standard additions method. 
 
Information about cigarette smoking status was based on data from a standardized 
interview. Current smokers were further classified according to the quantity of 
cigarettes smoked (<10 or >=10 cigarettes per day) based on information from the 
questionnaire. Leisure time physical activity was recorded in the questionnaire in four 
levels: sedentary, moderate, regular and athletic. Education level was also assessed on 
the questionnaire and was re-grouped into three categories: 7 years or 8 years was 
defined as low education; 12 years as medium education; and ≥3 years of college or 
completion of university graduate exam as high education.    
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At 20-year follow-up (70 years old) 
Participants at the age 70 investigation underwent a 75-gram OGTT with measurement 
of plasma glucose and immunoreactive insulin. The intra-individual coefficient of 
variation (CV) for fasting plasma glucose was 3.2%. The insulinogenic index, 
calculated as [(insulin at 30 min) – (insulin at 0 min)]/ [(glucose at 30 min) – (glucose 
at 0 min)], was used as a measure of glucose-stimulated insulin secretion indicative of 
β-cell function [124]. Proinsulin levels were measured by the two-site immunometric 
assay technique [122].  
 
In vivo sensitivity to insulin was determined by the euglycemic insulin clamp, 
according to the procedure described by DeFronzo et al. (1979) [10], but with a higher 
insulin infusion rate per body surface area to better suppress liver glucose output (56 
mU min-1 (m2)-1 instead of 40 mU min-1 (m2)-1). After a primary dose in the initial 10 
min, continuous infusion of insulin lasted for 110 min and hepatic glucose production 
was assumed to be entirely suppressed. Glucose disposal (M) was calculated as the total 
amount of glucose infused during the last 60 min (the steady state) of the clamp divided 
by kg body weight and minutes. The insulin sensitivity index (M/I ratio) was derived 
by dividing M by the steady-state mean insulin concentration (I). M/I thus represents 
the amount of glucose metabolized per unit of plasma insulin and was given in 100 × 
mg kg-1 min-1 mU-1 L.  
 
T2D was defined by elevated fasting glucose levels and/or use of anti-diabetic 
medicine. Elevated glucose levels were assessed as fasting plasma glucose ≥7.0 
mmol/L at age 70 (the same criterion was used at age 60 and age 77).  
 
Serum adiponectin was measured in plasma samples frozen at -70 °C for 11 ± 2 years, 
without previous thaw-freeze cycles and using a validated in-house time-resolved 
immunofluorometric assay (TR-IFMA) with reagents from R&D Systems (Abingdon, 
UK). The intra- and inter-assay coefficient of variation averaged less than 5% and 10%, 
respectively, as described in detail previously [125].  
 
3.3 Genotyping 
3.3.1 SP2 (Study II) 
2,865 blood-derived DNA samples from the SP2 Chinese participants were genotyped 
using Illumina HumanHap 550, 610 Quad, and 1Mduov3 BeadChips 
(http://www.illumina.com). The data went through quality control (QC) procedures 
which were described in details elsewhere [126]. SNPs with call rate < 0.95, minor 
allele frequency (MAF) < 0.01 or Hardy-Weinberg equilibrium (HWE) P-value < 
1×10-6 were filtered out. 431 individuals did not pass the QC due to high rates of 
missingness, excessive heterozygosity, cryptic relatedness, discordant ethnicity and 
gender discrepancy. Imputation was done with IMPUTE 
(http://mathgen.stats.ox.ac.uk/impute/impute.html) on 22 autosomes using NCBI build 
36 HapMapII CHB and JPT data (release 22) as the reference panel. Imputation results 
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of SNPs that were actually genotyped were replaced with experimentally determined 
genotypes before the association tests were conducted.  
 
3.3.2 ULSAM (Study III) 
The ULSAM participants at age 70 have undergone prior genotyping on the Human 
CardioMetabo beadchip (Metabochip; http://www.illumina.com/support/array/ 
array_kits/ humancardio-metabo_beadchip_kit.ilmn), which is designed to interrogate 
200,000 markers of interest for cardiovascular and metabolic diseases. Of the 1,221 
individuals with genotype data, we removed those with genotyping call rate < 0.99 (n = 
5), failing sex check (n = 1), close relatedness (n = 36), or large heterozygosity (n = 7). 
Quality control also ensured that all SNPs had good call rate (> 0.99) and did not 
deviate from HWE (P > 1 × 10-6). In total, genotypes of 183,357 SNPs were available 
for 1,175 individuals.  
 
3.4 Statistical analysis 
3.4.1 Path analysis in Study I 
Path analysis is an extension of regression analysis that simultaneously performs a 
series of regression analyses in complex networks. It is suitable to elucidate 
complicated inter-relationships between exposure variables of interest, multiple 
potential mediators, and health outcomes [127, 128]. Compared with ordinary 
regression analysis, path analysis has the advantage that it allows examination of the 
potential causal processes underlying an observed relationship and to estimate the 
relative importance of alternative paths of influence in a complicated system [127]. 
Particularly, path analysis also allows a disentanglement of the direct and indirect 
effects which can provide more insights into the complicated relationships.   
 
In our study path analysis was carried out to evaluate mediators of pair-wise ethnic 
differences in insulin resistance. A hypothetical model was proposed based on previous 
biological knowledge of the relationships between ethnicity, insulin resistance, 
adipokines and inflammation (Figure 3). BMI and the BMI-adjusted waist 
circumference (waistR) were chosen based on previous analysis results to represent 
body fatness in the model, total adiponectin level to represent adipokines, and  
inflammation was represented by CRP levels. Covariates considered included age, 
alcohol, smoking and physical activity. One-way arrows represent causal effects and 
two-way arrows represent correlations between the variables. Endogenous variables 
which are variables having at least one incoming arrow were depicted with associated 
error terms. 
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Figure 3. Full path diagram for the hypothetical model.  
 
We performed path analysis based on the full hypothesized model and paths with non-
significant path coefficients were removed to form a reduced model. Path analysis was 
performed again based on the reduced model. Model fit in comparison with the 
saturated and independent models was assessed based on the Bayesian Information 
Criterion (BIC).    
 
Amos 18.0 [129] was used to run the path analysis and Stata/SE 10.0 (Stata 
Corporation, College Station, Texas) for other analyses. All statistic tests were two-
sided and the level of significance was set at α=0.05. 
 
3.4.2 Genome-wide association analysis in Study II 
A genome-wide association study for total and HMW adiponectin was carried out on 
2,434 post-QC samples of the SP2 study. Adiponectin levels were natural log-
transformed and standardized to the z-scores. Additive genetic model adjusting for age 
and sex was used to test the associations and BMI was further adjusted for in a second 
model. The software used for the association study was SNPTEST v2.2.0 
(https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html). Samples 
genotyped on different chips were treated as separate studies and the results were meta-
analyzed under fixed-effect model weighted by inverse variance using METAL 
(http://www.sph.umich.edu/csg/abecasis/metal/). Sample size weighted meta-analysis 
was also performed and results were similar. Genomic control was applied to each 
study as well as the first-round meta-analysis results to correct for inflation.  
  
Genotypes for the top SNP from the meta-analysis, rs4783244 in the CDH13 gene, 
were successfully called for 2,429 individuals in the SP2 sample. Among them 39 had 
missing adiponectin levels and 4 had missing values for HOMA-IR. After further 
excluding those without age (n = 1), BMI (n = 2) and those taking diabetic medicine (n 
= 101), 2,282 individuals remained for the analysis.  
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For the replication analysis, a total of 3,290 Japanese from the Nomura [130] and AAC 
studies [131] (1,226 with both total and HMW adiponectin levels) and 1,610 Koreans 
in the Yangpyeong Study [132] (total adiponectin levels only) with clinical data and 
genotypes for rs4783244 were included.  
 
Levels of adiponectin were measured using different kits in the studies involved, so 
standardization to mean of zero and variance of one was uniformly performed on 
adiponectin and other metabolic variables to facilitate cross-study comparisons and 
meta-analyses. Multiple linear regressions based on additive and general genetic 
models were used with different adiponectin forms and metabolic risk factors (log-
transformed if necessary) as dependent variable and genotype, age and sex as 
independent variables. In addition, for metabolic traits, multivariable models that also 
included HMW adiponectin were evaluated. Bonferroni-corrected threshold α ≤ 5×10-8 
was considered genome-wide significant and α ≤0.005 was used as a cutoff for the tests 
on rs4783244 and 10 metabolic variables (calculated as 0.05/10).  All tests were 2-
sided. 
 
3.4.3 Mendelian randomization in Study III 
Mendelian randomization (MR) is a method that uses genetic variants (instrumental 
variables, IVs) as robust proxies for an environmentally modifiable exposure to assess 
and quantify potential causal relationships with health outcomes [133, 134]. Because 
genotypes that influence the exposure are assigned at conception, they are unlikely to 
be related to confounders such as lifestyle, socioeconomic and environmental risk 
factors or reverse causation. 
Hypothetical model 
Figure 4 illustrates the key relationships in the study of the influence of adiponectin on 
insulin sensitivity using a MR design. Solid arrows represent causal influences that are 
expected and dotted arrows are causal influences that are assumed not to exist. Genetic 
variants from ADIPOQ gene are used as IVs based on three main assumptions: (1) The 
IVs are robustly associated with the exposure of interest, i.e. adiponectin levels; (2) the 
IVs are independent of confounders for the association between adiponectin and insulin 
sensitivity in observational studies; (3) the IVs are independent of the outcome insulin 
sensitivity given adiponectin levels and the confounders. Moreover, we hypothesize 
that part of the effect of adiponectin on insulin sensitivity is mediated by adiposity 
which is represented by BMI and waist circumference.  
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Figure 4. Hypothetical model for the relationship between ADIPOQ, adiponectin and 
insulin sensitivity 
Selection of instrumental variables 
We searched the genomic region ± 50kb of the ADIPOQ gene and identified 16 SNPs 
that were present on the Metabochip. Pair-wise linkage disequilibriums (LDs) were 
then assessed and of the SNPs that were significantly associated with adiponectin, we 
selected rs17300539 and rs3774261 that were the top associated SNPs in their 
respective LD block as IVs. We also selected rs6444175 (r2 = 0.506 with rs3774261) 
and further generated an un-weighted allele score from rs17300539 and rs3774261 (r2 = 
0.137). Thus, we had three single SNPs and one allele score as IVs of serum 
adiponectin for subsequent MR analyses.  
 
Among the 1,221 participants, 199 were excluded for the following reasons: 
unavailable clamp data (n = 61), unavailable measurement of adiponectin (n = 15), or 
presence of T2D (n = 123). Of the remaining 1,022 participants, 942 participants with 
genotypes for ADIPOQ were eligible for the analysis.  
 
Adiponectin and insulin sensitivity index (M/I ratio) were natural log transformed and 
outliers (≥ 4SD from the mean) were truncated. The observed effects of adiponectin on 
M/I ratio, as well as effects of IVs on M/I ratio were obtained by linear regression 
under additive genetic models with adjustment for age. In further analyses, BMI and 
waistR were included as covariates into the model to evaluate effects independent of 
adiposity. Residual plots and cubic spline curves were plotted to visualize the degree of 
deviation from linearity. 
 
IV analysis was then performed using a two-stage least square (2SLS) approach with 
the Stata package ‘ivreg2’. In brief, the first stage was a conventional linear regression 
assessing the association between the SNPs and serum adiponectin. The predicted value 
of adiponectin from the model was saved and used as an independent variable in the 
second stage where the dependent variable was insulin sensitivity index (M/I ratio). 
This beta coefficient, or the IV estimate, reflects an unconfounded effect of genetically 
determined adiponectin level on insulin sensitivity. Endogeneity, or the difference 
between the IV estimate and the observed effect size, was examined by a Durbin-Wu-
Hausman Chi-square test implemented in the package. The percentage of change in 
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insulin sensitivity with x% increase in adiponectin estimated by each instrument was 
calculated by ((1 + x%)β-1) × 100% where β is the corresponding IV estimate. To test 
the generalizability of our results, we performed secondary analyses including the 123 
individuals with T2D. In order to examine potential effect modification by adiposity, 
we conducted a BMI-stratified analysis by defining overweight using the median BMI 
level in our sample (BMI ≥ 25.7kg/m2).  
 
Data were analyzed using Stata/IC (version 12.1, StataCorp, College Station, TX). 
Two-sided P-values < 0.05 were considered significant.  
 
3.4.4 Longitudinal analysis in Study IV 
Of the 2,322 participants at the age 50 examination, 393 individuals were excluded for 
the following reasons: serum selenium data not available (n = 274), presence of 
diabetes at baseline (n = 115) or missing glucose measurements (n = 8). In total, 1,925 
non-diabetic individuals formed the baseline study sample of the analysis in this study. 
After 20 years of follow-up, among the 1,211 participants at age 70, 1,026 had baseline 
serum selenium and 936 non-diabetic individuals were included for the analyses on 
glucose metabolic measures.  
 
Selenium levels were analyzed both as categorical variables in tertiles and as 
continuous variable (presenting betas per 1-SD increment). Continuous outcome 
variables were natural log transformed to improve normality of the distribution and also 
presented as change in SD-unit. Observations beyond 4SD from the mean were defined 
as outliers and truncated. Logistic regression analysis was used to examine the 
association between baseline selenium levels and risk of T2D at follow-up. The 
relationship between selenium and glucose metabolism measures at baseline and after 
20 years of follow up was examined by linear regression analysis. Two sets of models 
were used: model 1 adjusted for age at baseline; model 2 further adjusted for potential 
confounders including BMI, cigarette smoking, leisure time physical activity, and 
education levels. P-values for trend were calculated by assigning the median value to 
each selenium tertile category and modeling it as continuous variable.  
 
In a sensitivity analysis, we evaluated the association of baseline selenium levels and 
incident diabetes risk using the follow-up data at age 60 and 77 and compared the 
estimates with those from the age 70 follow-up.  
 
Analyses were performed using Stata/IC (version 12.1, StataCorp, College Station, 
TX). Two-tailed P-values < 0.05 were considered significant. 
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4 RESULTS & DISCUSSIONS 
4.1 Study I 
In this study we examined the mediating effects of body fatness, adiponectin and CRP 
on the differences of insulin resistance between three major ethnic groups in Singapore 
using path analysis. 
 
The degree of insulin resistance as reflected by HOMA-IR was highest in Asian 
Indians, intermediate in Malays, and lowest in Chinese. CRP was higher in Asian 
Indians and Malays than in Chinese, and Indian women had particularly high levels of 
CRP. Total and HMW adiponectin were highest in Chinese and lowest in Asian Indians 
when women were compared, but these ethnic differences were less marked among 
men. BMI was lowest in the Chinese and was similar for Malays and Asian Indians. 
However, Asian Indians had a larger WHR and a larger waist circumference than 
Malays and Chinese. WHR was not significantly different between Chinese and Malay 
men. 
 
By linear regression, ethnic difference in insulin resistance between Malays and 
Chinese disappeared after adjusting for BMI and waist or only BMI. The difference in 
HOMA-IR between Asian Indians and Chinese was also reduced after adjusting for 
BMI and waist, but remained statistically significant. Further adjustment for 
adiponectin and CRP levels explained slightly more of the ethnic difference in HOMA-
IR (Table 1).  
 
Table1. Associations between ethnicity and the HOMA-index of insulin resistance based on linear 
regression analysis with and without adjustment for potential intermediates. 
 Male Female 
 Model 1 Model 2 Model 3  Model 1 Model 2 Model 3 
Chinese Ref. Ref.  Ref.  Ref. Ref. Ref. 
Malay  0.17 -0.01 -0.01  0.28 -0.05 -0.02 
Asian Indian  0.48 0.25 0.23  0.50 0.17 0.15 
BMI, kg/m2  0.58 0.48   0.56 0.42 
WaistR, cm  0.13 0.10   0.13 0.10 
Adiponectin, ug/ml   -0.19    -0.21 
CRP, mg/l   0.11    0.13 
R2 0.06 0.38 0.42  0.12 0.38 0.44 
Model 1, unadjusted; Model 2, adjusted for BMI and waistR; Model 3, further adjusted for adiponectin 
and CRP. Italic values indicate statistically non-significant at α=0.05 level. 
 
Malay-Chinese comparison 
The effect of ethnicity on insulin resistance when Malays were compared with Chinese 
could be fully explained by the considered mediators as indicated by the non-significant 
direct path between ethnicity and HOMA-IR (Figure 5A and 5B).  
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Figure 5A, 5B. Path coefficients in the reduced models for Malay-Chinese comparison of differences in 
insulin resistance in men (A) and women (B). 
 
Ethnic Malays represent millions of people from different Southeast Asian Island 
populations including Malaysians, Filipinos and Indonesians who are experiencing a 
rapid increase in chronic disease burden [135]. Studies have demonstrated that overall 
ethnic Chinese from East Asia and Malays from Southeast Asia were genetically closer 
than either of them with Asian Indians [136]. More specifically, although culturally 
distinct, Malays in Singapore had a greater genetic similarity with Chinese than Asian 
Indians [136, 137]. Greater general adiposity of Malays as compared with Chinese 
explained their greater insulin resistance in our study and targeting excess weight gain 
in Malays should have high priority in public health efforts for chronic disease 
prevention [135]. 
 
Indian-Chinese comparison 
BMI alone accounted for a substantial proportion of the observed difference in insulin 
resistance between Asian Indians and Chinese. In addition, CRP, but not adiponectin, 
also contributed independently to the greater insulin resistance in Asian Indians as 
compared with Chinese. A smaller proportion was attributable to effects of adiposity 
through adiponectin and CRP and effects of CRP independent of BMI (Figure 5C and 
5D). 
 
Figure 5C, 5D. Path coefficients in the reduced models for Indian-Chinese comparison of differences in 
insulin resistance in men (C) and women (D). 
 
Two previous studies [30, 36] found higher insulin resistance in Asian Indians than in 
Chinese, which is consistent with our results. One of them [36] suggested that the 
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differences in total body fat mass could explain the higher insulin resistance in Asian 
Indians as compared with Chinese. In our study the difference in insulin resistance 
between Asian Indians and Chinese partly remained after adjusting for BMI and waist 
circumference. This discrepancy in results might be due to the use of anthropometry 
instead of direct body fat measurements in our study or the relative small sample size in 
the previous study. 
 
Indian-Malay comparison 
The difference in insulin resistance between Asian Indians and Malays was not 
mediated by BMI (Figure 5E and 5F) and this was in agreement with the similar BMI 
of Asian Indians and Malays. Instead, abdominal adiposity contributed to the greater 
insulin resistance in Asian Indian men and women as compared with their Malay 
counterparts. A substantial independent contribution of adiponectin and CRP to Indian-
Malay differences in insulin resistance was observed in women, but not in men. 
 
Figure 5E, 5F. Path coefficients in the reduced models for Indian-Malay comparison of differences in 
insulin resistance in men (E) and women (F). 
 
The comparison between Asian Indians and Malays highlighted the role of abdominal 
fat distribution in the contribution to insulin resistance and the effects of abdominal 
adiposity also appeared to mediate through adiponectin levels. In line with this finding, 
results from previous studies in Asian populations suggest that intra-abdominal fat may 
reduce adiponectin levels to a greater extent than subcutaneous fat [138-140] although 
other studies did not support this [141, 142]. 
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4.2 Study II 
In this study, we conducted a GWAS of total and HMW adiponectin in a Chinese 
population living in Singapore. With an extension to other East Asian populations, we 
also examined a genetic variant in CDH13 in relation to insulin resistance and 
associated metabolic traits. 
 
Among the populations involved in this study, Singaporeans were generally younger 
than Japanese and Korean participants, whereas Koreans had a higher BMI, higher 
triglyceride levels, higher HOMA-IR, and lower HDL-cholesterol (HDL-C) levels than 
the other populations. The substantial differences in adiponectin levels between study 
populations may be partly due to differences in laboratory methods and have been 
addressed by standardization of adiponectin levels in the data analysis. As expected, 
blood adiponectin levels were inversely correlated with insulin resistance (measured by 
HOMA-IR or fasting insulin), fasting glucose, triglycerides and CRP and directly 
correlated with HDL-C in our study populations.  
 
GWAS results 
In the GWAS in Singapore Chinese, signals reaching genome-wide significance (5 ×10-
8) mapped exclusively to the CDH13 and ADIPOQ gene (Figure 6). The strongest 
signal in CDH13 was rs4783244 located in the intron region. With regard to other 
previously reported loci, associations with total and HMW adiponectin levels reached 
genome-wide significance for ADIPOQ (rs10937273) and we observed nominally 
significant associations for GPR109A (rs601339), CMIP (rs2925979) and PEPD 
(rs731839). We focused on the top hit CDH13 SNP rs4783244 in this study.  
 
 
Figure 6. Manhattan plot for the whole-genome association with HMW adiponectin in Singapore 
Chinese.  
 
Association of the CDH13 variant with different adiponectin forms 
In the combined data from Singapore Chinese, Japanese and Korean cohorts,  total 
adiponectin levels significantly decreased by 0.34 SD on the log scale for each 
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additional T allele rs4783244 in CDH13 (95% CI: -0.38 to -0.30, Table 2). This 
CDH13 variant was even more strongly associated with HMW adiponectin levels and 
the HMW-to-total adiponectin ratio based on the Singaporean Chinese and Japanese 
data. Adjustment for BMI did not substantially affect these effect estimates and similar 
results were obtained for the general genetic model. The CDH13 rs4783244 variant 
explained more than 4% of variation in total adiponectin (Singapore: 4.5%, Korea: 
5.5%, Japan: 4.1%) and more than 6% of variation in HMW adiponectin levels 
(Singapore: 8.3%, Japan: 6.5%). 
 
Table 2. Association between rs4783244 in CDH13 and different forms of adiponectin 
 N β (95% CI) P-value 
Total adiponectin 
Singaporean Chinese 2,282 -0.32 (-0.37, -0.26) 2.7 × 10-27 
Japanese 1,266 -0.34 (-0.42, -0.27) 4.2 × 10-19 
Koreans 1,610 -0.37 (-0.44, -0.30) 2.4 × 10-25 
Meta-analysis 5,158 -0.34 (-0.38, -0.30) 2.0 × 10-70 
HMW adiponectin 
Singaporean Chinese 2,282 -0.43 (-0.48, -0.37) 1.7 × 10-51 
Japanese 3,290 -0.38 (-0.42, -0.34) 3.3 × 10-64 
Meta-analysis 5,572 -0.40 (-0.43, -0.36) 1.1 × 10-117 
HMW-to-total adiponectin ratio 
Singaporean Chinese 2,282 -0.48 (-0.54, -0.43) 9.7 × 10-62 
Japanese 3,290 -0.36 (-0.44, -0.29) 1.7 × 10-19 
Meta-analysis  5,572 -0.44 (-0.49, -0.40) 3.2 × 10-83 
Results are age and sex adjusted. Total and HMW adiponectin were natural log transformed 
and all the adiponectin forms were standardized to the z-scores. An additive genetic model is 
assumed and each β represents the effect of one copy of the T allele on the respective form of 
adiponectin.  
 
Association of the CDH13 variant with metabolic traits 
At a Bonferroni-corrected threshold of P ≤ 0.005, no significant association between 
rs4783244 in CDH13 and metabolic risk factors was observed in Singaporean Chinese 
or in Japanese (Model 1). Because CDH13 is known to code for a receptor for HMW 
adiponectin, we reassessed these associations after adjustment for HMW adiponectin 
levels (Model 2). In a meta-analysis of the Singaporean Chinese and Japanese samples, 
the minor allele T in rs4783244 was significantly associated with lower BMI (β = -
0.15, 95% CI: -0.19 to -0.11, P = 3.5×10-14), lower HOMA-IR (β = -0.16, 95% CI: -
0.20 to -0.12, P = 9.2×10-16), higher HDL-C (β = 0.16, 95% CI: 0.12 to 0.19, P = 
2.1×10-17) and lower triglycerides (β = -0.16, 95% CI: -0.19 to -0.12, P = 1.3×10-16) 
when HMW adiponectin levels were adjusted for. After further adjusting for BMI, 
associations were weaker, but remained significant (Figure 7). These associations were 
significant but also weaker when we adjusted for total adiponectin instead of HMW 
adiponectin. In a sensitivity analysis, there was minimal difference in effect estimates 
between fixed- and random-effect meta-analysis and the estimates retained genome-
wide significant with random-effect analysis. 
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Figure 7. Effect estimates of rs4783244 in CDH13 on selected metabolic traits across studies; age, sex 
and HMW adiponectin adjusted.  
 
Results from previous studies also provided little support for an association between 
variants at the CDH13 locus and metabolic traits. In Filipino women, no significant 
associations with metabolic risk factors were detected for rs3865188 in CDH13 (LD 
with rs4783244, r2 = 0.85) except for a nominal association (P = 0.042) with waist 
circumference [115]. Similarly, a Swedish study reported that rs11646213, a SNP 
upstream of CDH13, in minimal LD with rs4783244 (r2 = 0.08), was not associated 
with metabolic risk factors [143]. In a Taiwanese study, the significant associations 
between rs4783244 and waist circumference, glucose and triglyceride levels did not 
remain after adjustment for BMI, although the adiponectin-lowering T allele was 
paradoxically still associated with a reduced risk for diabetes, the metabolic syndrome 
and stroke [116]. 
 
Recently, Japanese researchers reported an association between another CDH13 SNP 
(rs12051272) and BMI, fasting insulin, fasting glucose, HOMA-IR, and fasting 
triglycerides only after controlling for adiponectin levels [114]. This SNP is in close 
proximity and moderate LD (r2 = 0.66) with rs4783244, which we studied. Together 
with our findings, current evidence suggests a complex relationship between variants at 
the CDH13 locus and metabolic traits that is only evident after controlling for their 
effects on blood adiponectin levels. 
 
Hypothetical mechanism 
The association between the variants at CDH13 and plasma HMW adiponectin may be 
explained by the function of the T-cadherin receptor that it encodes. T-cadherin is a 
receptor for hexameric and HMW adiponectin that is expressed in the vasculature 
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[144], cardiac myocytes [145] and epithelial cells in the lung [146]. We believe that the 
T allele at rs4783244 is associated with increased binding of HMW adiponectin to the 
T-cadherin receptor resulting in the sequestration of HMW adiponectin in these tissues, 
thus removing it from the blood. Consistent with this explanation, ablation of the T-
cadherin receptor increased plasma adiponectin levels in mice [144-146].  
 
To explain the paradoxical observation that the T allele at rs4783244 that is associated 
with lower blood levels of  HMW adiponectin is associated with a more favorable 
metabolic profile than would be expected based on HMW adiponectin levels, we 
hypothesize that the rs4783224 variant at the CDH13 locus may have an indirect effect 
on an individual’s sensitivity to circulating adiponectin. In this hypothesis, the 
chronically low levels of plasma adiponectin associated with the T allele may result in 
up-regulation of adiponectin receptors AdipoR1/R2. Consistent with this proposed 
mechanism, chronic elevation of plasma adiponectin led to down regulation of 
AdipoR2 in adipose tissue in mice [147]. Furthermore, the expression of AdipoR1/R2 
was up-regulated in insulin-resistant women with the polycystic ovary syndrome [148], 
who would be expected to have low blood adiponectin levels. The greater expression of 
adiponectin receptors could counter-balance the low adiponectin levels resulting in the 
lack of association between rs4783244 and the metabolic profile in unadjusted 
analyses. However, when the blood adiponectin levels are controlled for, then the 
greater ‘adiponectin sensitivity’ results in an association between the T allele and a 
more favorable metabolic profile.  
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4.3 Study III 
In this study, we examined the causal effect of increased adiponectin levels on 
improved insulin sensitivity in humans using a Mendelian randomization approach with 
ADIPOQ SNPs as instruments in a population-based cohort study of 71-year-old men 
in Sweden.  
Association between the instruments and serum adiponectin 
Table 3 shows the 16 ADIPOQ SNPs available on the Metabochip and their 
associations with adiponectin levels in the ULSAM cohort. Based on LD structure, they 
were assigned to 11 different blocks. Seven SNPs belonging to two different LD blocks 
showed highly significant associations with serum adiponectin (all P ≤ 4.8 × 10-7). The 
three SNPs chosen as instrumental variables, namely rs17300539, rs3774261 and 
rs6444175 were all strongly associated with adiponectin levels. As expected, the allele 
score generated from rs17300539 and rs3774261 was even more strongly associated 
with adiponectin level as compared with each of the single ADIPOQ SNPs. The 
instruments explained 3.5 to 6.0% (rs17300539: 4.3%, rs3774261: 3.8%, rs6444175: 
3.5%, all three SNPs combined: 6.0%) of the total variance in adiponectin levels. 
 
Table 3. ADIPOQ SNPs available on the Metabochip and their associations with serum adiponectin. 
SNP or allele 
score 
Position on 
chr3 
Alleles* EAF HWE  
P-value 
Association with adiponectin,  
age adjusted 
     Beta (95% CI) P-value 
rs3917086        (1) 188007420 A/C 0.03 0.621 0.02 (-0.08, 0.12) 0.668 
rs864265          (2) 188036986 T/G 0.15 0.015 -0.06 (-0.10, -0.01) 0.020 
rs822387          (3) 188038731 C/T 0.07 0.660 0.16 (0.10, 0.22) 4.8 × 10-7 
rs17300539‡    (3) 188042154 A/G 0.07 0.189 0.21 (0.14, 0.27) 1.1 × 10-10 
rs16861209      (3) 188045808 A/C 0.07 0.088 0.21 (0.15, 0.28) 1.5 × 10-10 
rs16861210      (3) 188049192 A/G 0.08 0.550 0.19 (0.13, 0.25) 1.1 × 10-9 
rs16861194      (4) 188042119 G/A 0.09 0.855 -0.05 (-0.11, 0.01) 0.106 
rs822396          (5) 188049571 G/A 0.17 0.475 0.01 (-0.03, 0.06) 0.562 
rs3774261‡      (6) 188054253 A/G 0.38 0.950 0.11 (0.07, 0.14) 1.3 × 10-9 
rs6773957        (6) 188056399 A/G 0.38 0.950 0.11 (0.07, 0.14) 1.4 × 10-9 
rs6444175‡      (6) 188062438 A/G 0.29 0.438 0.11 (0.08, 0.15) 5.3 × 10-9 
rs3774262        (7) 188054508 A/G 0.09 0.185 0.03 (-0.03, 0.09) 0.327 
rs9853541        (8) 188095161 A/G 0.38 0.121 0.00 (-0.04, 0.04) 0.927 
rs11708293      (9) 188096021 G/A 0.04 1.000 -0.04 (-0.13, 0.04) 0.322 
rs11716002    (10) 188096058 G/A 0.24 0.105 0.01 (-0.03, 0.05) 0.616 
rs17301514    (11) 188096103 A/G 0.13 1.000 0.01 (-0.04, 0.06) 0.757 
Allele score§     0.40 (0.30, 0.51) 1.2 × 10-13 
EAF, Effect allele frequency. SNPs were first sorted based on physical position in the ADIPOQ gene and 
then aggregated by LD group indicated by the number in the bracket. All the SNPs had call rate >0.96. 
*The first allele is the effect allele. ‡SNPs selected for instrumental variable analysis. §The allele score 
was created using genotypes for rs17300539 and rs3774261 (R2 = 0.137).  
 
The three SNPs selected as IVs have been repeatedly reported for their association with 
adiponectin in individuals of European descent [109, 110, 149-152]. This confirms that 
the SNPs we selected are robust instruments for adiponectin levels in European 
populations. 
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Association between the instruments and insulin sensitivity 
All the instrumental variables including the three ADIPOQ SNPs and the allele score 
were significantly associated with insulin sensitivity represented by the M/I ratio (P ≤ 
0.022 for all SNPs and P = 8.0 × 10-4 for the allele score). Adjustment for adiposity 
represented by BMI and waistR weakened these associations, but some of the 
instruments remained significantly associated with the M/I ratio (rs6444175, P = 0.011; 
allele score, P = 0.042).  
 
Studies of the relationship between ADIPOQ and insulin sensitivity in candidate gene 
studies have been less consistent [153]. The 3q27 region in which the ADIPOQ gene is 
located was reported for its linkage signal with seven metabolic traits, and was 
suggested for an association with obesity and insulin sensitivity [154]. However, 
individual ADIPOQ SNPs, including some of the IVs in our study, did not show an 
association with parameters for glucose and insulin metabolism [109, 111, 152]. 
However, in a recent large study, Dastani et al. demonstrated that several individual 
SNPs which were significant in their GWAS of adiponectin levels, including a few 
ADIPOQ SNPs, were associated with T2D and related traits. Furthermore, they found a 
multi-SNP genotypic risk score based on the identified hits to be strongly associated 
with metabolic traits related to insulin resistance [117]. Therefore, even though 
ADIPOQ has been established as major determinant of adiponectin levels, its 
associations with measures of insulin sensitivity have not been consistent which may 
have been due to lack of statistical power to detect this indirect effect. Of note, prior 
studies have not assessed associations of ADIPOQ variants and insulin sensitivity 
measured with intravenous methods in a larger study sample.  
 
Instrumental variable analysis of the effect of adiponectin on insulin sensitivity  
To examine the potential causal effect of adiponectin on insulin sensitivity in an IV 
analysis, we assessed the first-stage F-statistic in which an empirical value >10 
indicates sufficient strength of the genetic variant as a proxy of the exposure. The large 
F-statistics ensured that the SNPs chosen were strong instruments for adiponectin levels 
(Table 4).  
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Table 4. Instrumental variable estimated and observed association between adiponectin and insulin 
sensitivity. 
  IV estimate Observational estimate  
Instrumental 
variable 
First stage 
F statistic 
Beta (95% CI) P-value Beta  
(95% CI) 
P-value Endogeneity† 
P-value 
Age adjusted 
rs17300539 42.6 0.47 (0.10, 0.84) 0.014 
0.50  
(0.42, 0.58) 
1.2 × 10-33 
0.878 
rs3774261 37.6 0.68 (0.28, 1.08) 9.1 × 10-4 0.364 
rs6444175 34.7 0.81 (0.38, 1.23) 2.1 × 10-4 0.136 
Allele score* 56.7 0.60 (0.27, 0.93) 3.3 × 10-4 0.528 
Age, BMI and waistR adjusted 
rs17300539 38.5 0.27 (-0.08, 0.61) 0.131 
0.28  
(0.21, 0.34) 
1.3 × 10-14 
0.955 
rs3774261 29.3 0.39 (-0.01, 0.78) 0.055 0.572 
rs6444175 28.1 0.55 (0.13, 0.96) 0.010 0.178 
Allele score 46.7 0.34 (0.03, 0.65) 0.034 0.677 
*The allele score was created using genotypes for rs17300539 and rs3774261 (R2 = 0.137). †Endogeneity was assessed 
by Durbin-Wu-Hausman test and reflects whether the difference between the IV estimate and the observational estimate 
was statistically significant. 
 
The IV-estimated effect size of adiponectin levels on insulin sensitivity was highly 
significant and consistent for all instruments. In addition, endogeneity tests suggested 
there was no statistical difference between the IV estimate and the observational 
estimate (Table 4). This was consistent for each of the individual SNP instruments and 
also the allele score, demonstrating that genetically determined adiponectin levels affect 
insulin sensitivity to the same degree as expected based on the observed association. In 
our secondary analyses including individuals with T2D, the results were similar to 
those from our main analyses. 
 
For some of the IVs, we still observed an association between the IV-estimated 
adiponectin and insulin sensitivity after adjustment for BMI and waistR (Table 4), 
although the effect sizes were substantially attenuated. This suggests that at least part of 
the causal beneficial effect of adiponectin levels on insulin sensitivity was mediated by 
lower adiposity as measured by BMI and waist circumference. BMI-stratified analysis 
suggested that the association between increased adiponectin levels and higher insulin 
sensitivity was stronger in the group with higher BMI, for which the observed causal 
relationship between adiponectin and insulin sensitivity also persisted. However, in the 
group with lower BMI, we did not have enough power to robustly confirm or refute an 
association due to limited sample size.  
 
The role of adiposity is important to dissect the causal relationship between adiponectin 
and insulin sensitivity, as will be discussed in Future perspectives.   
 
Estimated impact of adiponectin on insulin sensitivity 
Based on the IV estimates in the age-adjusted  model (ranged between 0.47 and 0.81), 
we estimated the relationship between percent change in adiponectin levels and 
corresponding percent change in insulin sensitivity. For example, a 10% increase in 
serum adiponectin level would lead to an improvement of insulin sensitivity ranging 
between 4.6% and 8.0%. Similarly, excluding the mediation through obesity, the 
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percent increase in insulin sensitivity associated with a 10% elevation in adiponectin 
level was estimated to be between 2.6% to 5.3%. However, due to the large confidence 
intervals for the IV estimates, these numbers should be interpreted with caution.  
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4.4 Study IV 
In this study, we examined relations between serum selenium levels and measures of 
glucose and insulin metabolism, as well as risk of diabetes after 20 years of follow-up 
in 1,925 participants from the ULSAM cohort. 
 
The mean concentration of serum selenium in our study population was 75.6 μg/L. At 
baseline, serum selenium was not significantly associated with fasting glucose levels or 
glucose tolerance represented by the K-value from the IVGTT. Higher serum selenium 
levels were associated with a lower insulin peak during the IVGTT indicating lower 
early insulin response. This association persisted after adjustment for potential 
confounders (selenium as continuous variable, standardized β = -0.08; 95% CI: -0.14 to 
-0.03, P for trend = 0.026). However, this is likely a chance finding due to the multiple 
tests we performed and does not have an obvious biological meaning. Selenium was 
not substantially associated with HOMA measures of insulin resistance or insulin 
secretion.  
 
At follow-up after 20 years, we observed no clear associations with any glucometabolic 
traits as well as adiponectin levels. Among 1,024 individuals with baseline selenium 
levels and follow-up data, 88 developed diabetes. Selenium levels were not 
substantially associated with a higher risk of diabetes during follow-up in either age-
adjusted or multivariable models (Table 5). Analysis with selenium as a continuous 
variable also revealed no association of baseline selenium levels with incident risk of 
diabetes.  
 
Table 5. Association of baseline serum selenium (at age 50 years) with diabetes risk during follow-up at 
age 60 years, age 70 years and age 77 years. 
Study   N Low Se 
tertile 
Middle Se 
tertile 
High Se tertile Continuous Se 
(per SD of Se) 
P for 
trend* 
Age 60 
exam 
 
Diabetes 
(yes/no) 
53/1,486 15/501 15/489 23/496   
Model 1 1,539 1 0.99 (0.48, 2.05) 1.51 (0.78, 2.92) 1.15 (0.87, 1.52) 0.201 
Model 2 1,539 1 0.91 (0.43, 1.95) 1.28 (0.64, 2.61) 1.11 (0.81, 1.51) 0.437 
Age 70 
exam 
 
Diabetes 
(yes/no) 
88/936 24/302 33/314 31/320   
Model 1 1,024 1 1.31 (0.76, 2.27) 1.21 (0.69, 2.10) 1.04 (0.82, 1.31) 0.544 
Model 2 1,024 1 1.31 (0.73, 2.36) 1.25 (0.68, 2.27) 1.06 (0.83, 1.38) 0.497 
Age 77  
exam 
Diabetes 
(yes/no) 
91/565 27/179 34/182 30/204   
Model 1 656 1 1.23 (0.71, 2.14) 0.97 (0.55, 1.70) 0.97 (0.76, 1.25) 0.876 
Model 2 656 1 1.16 (0.65, 2.08) 0.97 (0.54, 1.75) 0.96 (0.74, 1.25) 0.880 
Logistic regression was used and results as OR (95% CI). The low Se tertile is the reference category. Model 1: 
adjusted for age; Model 2: adjusted for age at baseline, BMI, cigarette smoking, leisure time physical activity, and 
education at the baseline examination. 
 
In sensitivity analyses, 53 individuals free of diabetes at baseline developed diabetes by 
the age 60 follow-up. A total of 91 incident diabetes cases were identified in the age 77 
examination after 27 years of follow-up since baseline at age 50. The odds ratio 
estimates based on continuous selenium levels were similar to those observed at age 70 
with no evidence for an association of selenium levels with incident diabetes (Table 5).  
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Two large RCTs to address the effect of selenium on future risk for disease have been 
conducted to date, including the Selenium and Vitamin E Cancer Prevention Trial 
(SELECT) [75] and the Nutritional Prevention of Cancer (NPC) trial [76]. Results from 
these two trials suggested a lack of beneficial effect of selenium supplementation on 
T2D and the NPC trial reported that the risk significantly increased with greater 
baseline selenium levels defined by tertiles [76]. To be noted, both trials were 
conducted in the United States where selenium supplementation is common.  
 
Comparison and interpretation of the findings for the effects of selenium in different 
studies is not straightforward. Firstly, baseline selenium levels are greatly different 
across populations, due to factors such as soil selenium content, dietary patterns, 
selenium supplements used and genetics [155, 156]. For example, selenium intakes are 
considerably lower in Europe than in USA and Canada [155]. In Sweden, the estimated 
intake is 31 to 38 μg per day [156] while in USA the daily intake ranged from 60 to 220 
μg [155]. Serum or plasma selenium concentrations also vary substantially by country 
[155, 157]. In our cohort, serum selenium averaged 76 μg /L, which is even lower than 
most participants of low baseline selenium levels in SELECT and NPC trial [75, 76]. It 
is possible that selenoenzyme activities have already reached a maximum in the trials 
[158], whereas in most of the ULSAM participants it did not.  
 
Secondly, selenium supplementation in the clinical trials used high doses and the 
resulting circulating selenium levels were substantially higher than would result from 
dietary intake only. This is even more pronounced if the baseline levels were already 
different. Selenium is a trace element with a relatively narrow range between 
deficiency and toxicity [159, 160]. Protective effects of selenium on diabetes and 
glucose metabolism, if these exist, may only be found at optimal levels that enhance 
selenoprotein activities. A loss of benefit or even adverse effects could occur outside 
the optimal range. In a prospective study of similar design and baseline selenium levels 
to our study, no significant association was detected between selenium and 
hyperglycemia [161]. Therefore, the role of selenium in the development of diabetes 
and hyperglycemia remains to be elucidated.  
 
Insulin resistance can be induced by ROS [162] and several selenoproteins have an 
antioxidant property [163]. Thus, selenium could exert a protective effect on insulin 
sensitivity by alleviating oxidative stress. However, experimental evidence has been 
conflicting. On the one hand, selenoproteins such as GPx1 and selenoprotein P have 
been shown to interfere with insulin signaling and contribute to the development of 
insulin resistance [70, 164-166]. Mice overexpressing GPx1developed diabetic 
phenotypes, including hyperglycemia, increased insulin production and insulin levels, 
and elevated β-cell mass [167, 168]. On the other hand, selenium-containing 
micronutrients such as sodium selenate can serve as an insulin-mimetic [69]. Sodium 
selenate has been demonstrated to improve peripheral insulin sensitivity measured by 
the euglycemic clamp in rats [169] and increased the expression of PPAR-γ, a 
transcription factor that sensitizes the body to insulin, in diabetic db/db mice [170]. One 
human trial found that adding selenium to a hypocaloric diet led to a borderline 
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significant reduction of fasting insulin and HOMA-IR in 84 centrally-obese women 
[171]. 
 
Adiponectin is an adipocyte-secreted hormone and plays an important role in glucose 
metabolism, especially in the regulation of insulin sensitivity [95, 96, 172, 173]. 
Selenium treatment  decreased adiponectin levels possibly by suppressing adiponectin 
production in Otsuka Long-Evans Tokushima Fatty (OLETF) rats [174]. A few studies 
have examined the effects on adiponectin levels when selenoprotein P, a major class of 
selenoproteins [67], was knocked out/down in mice, but results from different studies 
have been inconsistent [175, 176]. A human study involving 36 patients with diabetes 
reported an inverse association of selenoprotein P with circulating adiponectin, but not 
with the quantitative insulin sensitivity index [175]. In a recent randomized trial from 
UK where selenium status is comparable to Sweden, baseline plasma selenium was 
inversely associated with adiponectin concentrations, but selenium supplementation of 
six months at doses 100, 200 and 300 μg/day had no effect on adiponectin levels [177]. 
Results of our study did not support an association between baseline selenium levels 
and adiponectin levels after 20 years of follow-up, but further research is needed to 
clarify the inconsistency of results across studies.  
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4.5 Strengths and limitations 
4.5.1 Strengths 
A major strength of the SP2 study is the inclusion of a multi-ethnic sample consisting 
of Chinese, Malays and Asian Indians, which well represents the populations in East 
and South East Asia. Their susceptibility to (central) obesity, insulin resistance, as 
discussed in Study I, makes it an important research focus to study Asians for the 
etiology and prevention of T2D. In addition, HMW adiponectin was measured together 
with total adiponectin levels in all the participants with blood samples. This is valuable 
because HMW adiponectin has been shown to be the form of highest bioactivity and a 
stronger association with various metabolic traits [83, 100-102]. 
The strengths of the ULSAM study include the longitudinal design and the long follow-
up period. Moreover, the study was undertaken in a homogeneous, age-standardized 
sample from Uppsala in Sweden, and therefore population stratification which could, 
for example, violate assumptions of Mendelian randomization in Study III is unlikely. 
Moreover, the ULSAM cohort has detailed measurements of many metabolic variables 
related to insulin and glucose metabolism. Importantly, it is the largest single-center, 
population-based cohort in the world with insulin sensitivity measured by the 
euglycemic insulin clamp technique. Compared with indirect measurements and 
surrogate indices, this method directly measures whole body glucose disposal at a given 
level of insulinemia under steady-state conditions and is therefore regarded as the gold 
standard for measuring insulin resistance [178]. This partially compensated for the 
relatively modest sample size of the ULSAM study when analyzing insulin sensitivity 
as the main outcome in Study III and Study IV.  
4.5.2 Limitations 
To date, the SP2 study only contains cross-sectional data and this does not allow us to 
study the temporal relationship between exposure and outcome. This study also 
suffered from a moderate response rate (~60%). In 1998, non-participants were 
contacted and they were similar to the participants for the collected information 
including demographic, socio-economic status, diabetes and hypertension status. 
However, it is not known whether they differ from the participants in other aspects.   
 
The ULSAM study was based on elderly men of Northern European descent and hence, 
the generalizability to women, other age groups and other ethnicities is unknown. In 
addition, there was substantial loss to follow-up in the two most recent investigations, 
although this thesis only used studies with participation rate above 60%.   
 
In both SP2 and ULSAM studies, adiponectin was only measured once due to cost, 
research interest and other reasons. It would be desirable to have repeated 
measurements of adiponectin in future cohort studies, so as to discern changes over 
time and evaluate its temporal relationship with metabolic outcome of interest. Besides, 
in both studies, adiposity was assessed by anthropometry instead of direct techniques 
which are more accurate but were not feasible in our relatively large study. It would be 
ideal to measure adiposity in different depots and differentiate visceral abdominal fat 
from subcutaneous fat. As another limitation, in ULSAM dietary intake was not 
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assessed at baseline. Due to this, in study IV we cannot rule out the possibility of 
confounding by unmeasured dietary factors or other unmeasured or imperfectly 
measured confounders.  
 
Underlying assumptions 
We proposed the path model in Study I based on previous research findings, but the 
studied risk factors might not be in the causal pathway towards insulin resistance or 
T2D. In addition, other adipokines and inflammatory markers may also contribute to 
ethnic differences in insulin resistance [179], but were not considered in our study.  
 
In Study II, we started with a GWAS to search for genetic variants associated with 
adiponectin levels. As is for all GWAS, this is based on the ‘common disease common 
variants’ assumption. We did identify CDH13 and a few other loci strongly associated 
with total and HMW adiponectin, but rarer variants (MAF < 1%) are unlikely to be 
captured by the GWAS approach due to a lack of statistical power.  
  
The choice of the instrumental variables and the fulfillment of the assumptions of the 
Mendelian randomization are critical in Study III. ADIPOQ is the most established 
gene influencing adiponectin levels and genetic variation in ADIPOQ affects 
adiponectin production without affecting insulin sensitivity in other known ways. 
Therefore, by focusing on ADIPOQ, concerns over the strength and potential 
pleiotropic effects of the instrument could largely be eliminated. 
 
For study IV, our longitudinal assessment of selenium as an exposure in relation to 
glucometabolic profiles and diabetes risk was based on serum selenium measured at 
baseline, which assumes that this single measurement reflects dietary selenium intake 
over the long follow-up years. Even though serum selenium is a good indicator of long-
term dietary selenium intake, it is still desirable to have repeated sampling to minimize 
the possibility of residual confounding due to substantial changes in individual intake 
of this element.  
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5 CONCLUSIONS 
 
I. Mediators of ethnic differences in insulin resistance differed markedly 
depending on the ethnic groups compared. General adiposity explained the 
difference in insulin resistance between Chinese and Malays, whereas 
abdominal fat distribution, inflammation, and unexplained factors 
contributed to excess insulin resistance in Asian Indians as compared with 
Chinese and Malays. Interventions targeting excess weight gain can 
reduce ethnic disparities in insulin resistance among Asian Indians, 
Chinese and Malays.  
 
II. A genetic variant in CDH13 explains a substantial part of variation in 
HMW adiponectin levels in East Asian populations. However, this effect 
of CDH13 on circulating HMW adiponectin levels did not appear to 
translate into effects on insulin-resistance related metabolic traits, 
suggesting that compensatory mechanisms exist that lead to greater 
‘adiponectin sensitivity’. 
 
III. Genetically determined adiponectin levels influence insulin sensitivity to 
the same degree as the observed epidemiological associations. The 
observed association between higher adiponectin levels and increased 
insulin sensitivity is likely to represent a causal relationship. 
 
IV. No effect of selenium intake on insulin sensitivity, insulin secretion, or 
risk of type 2 diabetes was identifiable in older Swedish men. Taken 
together with prior studies including randomized clinical trials, the body 
of evidence argues against a role for selenium supplementation as a broad 
approach to prevent diabetes in the older population. 
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6 FUTURE PERSPECTIVES 
6.1 Clinical utility of adiponectin as a biomarker 
Clinical trials usually involve substantial investment of resources. Validated 
biomarkers, when used in clinical studies, can help detect the efficacy of the drug 
early (for example, in stage I or stage II) that would otherwise only be known at late 
stages and thus reduce unnecessary cost. In addition, a good predictive biomarker 
could aid in the selection of patients to treat [180].  
 
Thiazolidinediones (TZDs) are synthetic ligands of PPAR-γ that have been widely 
used to treat diabetes [181] and many studies have shown that adiponectin levels 
increased in response to TZD treatment [20, 182]. Thus adiponectin could be viewed 
as a promising biomarker of PPAR–γ activation.  
 
Despite the robust inverse association of adiponectin with insulin resistance and T2D, 
current research largely focuses on pathogenesis of this protein and studies on the 
clinical utility of adiponectin in predicting the risk of T2D are still lacking. Because 
adiponectin correlates well with established metabolic risk factors of T2D [90, 95], it 
remains to be assessed in a formal statistical approach whether adiponectin improves 
risk prediction in addition to existing predictors in a cost-effective manner.   
 
Adiponectin has also been studied as a biomarker for gestational diabetes (GDM). 
Since the placenta does not produce adiponectin, plasma adiponectin which solely 
comes from the adipose tissue is an independent marker of maternal adipose 
homeostasis [183]. In a study involving 445 pregnant women, decreased maternal 
adiponectin levels positively correlated with GDM diagnosed in the second trimester 
and was proposed to be a potential early marker of susceptibility to GDM [184].  
 
In view of adiponectin’s anti-diabetic property, interestingly and paradoxically, 
elevated adiponectin levels have been associated with increased risk of all-cause and 
cardiovascular mortality for individuals at-risk, for example, elderly people [185], 
those with renal diseases [186], and heart failure [187, 188]. It is possible that 
adiponectin levels increase in response to vascular stress as a compensatory effect or 
due to adiponectin resistance, but further studies are needed to better understand this. 
Therefore, the effect of adiponectin on cardiovascular diseases should be interpreted 
with caution at the moment.  
 
6.2 Further characterization of the causality between adiponectin and 
insulin sensitivity 
Our results in Study III support the hypothesis that adiponectin levels are causally 
related to the degree of insulin sensitivity in humans. However, the role of adiposity in 
the relationship between adiponectin and insulin sensitivity is debatable. The degree of 
adiposity is associated with both adiponectin levels and insulin sensitivity [90, 172, 
189] and thus could confound the adiponectin-insulin sensitivity relationship. What we 
observed in Study III was attenuated associations of the SNPs and insulin sensitivity 
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with adjustment for adiposity, which does not support a role of adiposity as a 
confounder, but instead implies it as a partial mediator for the relationship between 
adiponectin and insulin sensitivity. Previous studies also suggested that adiponectin 
influenced insulin sensitivity independent of adiposity [21, 95]. As proposed by 
Kadowaki and et al., obesity caused by environmental risk factors could interact with 
genetic factors leading to reduced adiponectin levels, which in turn plays a role in the 
development of insulin resistance, T2D and metabolic disease [97]. Due to limited 
statistical power, we were not able to fully explore the role of adiposity in the causal 
effect of adiponectin on insulin sensitivity, but suggested it as a partial mediator which 
might work by antagonizing the secretion of pro-inflammatory cytokines through 
reduced adiposity.  
 
Therefore, in order to establish causality, further studies on the inter-relationship 
between adiposity, adiponectin and insulin sensitivity are warranted. 
 
6.3 Adiponectin as a therapeutic target in diabetes treatment 
Experimental studies have provided convincing evidence for an effect of adiponectin 
on insulin sensitivity when adiponectin levels are altered in transgenic and 
adiponectin-deficient models [190, 191]. In a recent study using adiponectin knockout 
mice, high-fat diet and adiponectin supplementation were associated with changes in 
lipid, carbohydrate and amino acid metabolomic profiles in skeletal muscle. 
Conversely, the replenishment of adiponectin reversed euglycemic clamp-measured 
insulin sensitivity by a certain degree [192].  
 
One of the logical strategies for the treatment of insulin resistance and T2D is to 
increase adiponectin levels. Direct administration of adiponectin is difficult, but 
therapeutic agent that target adiponectin signaling could achieve this. For example, 
the anti-diabetic drug TZDs, are known to ameliorate insulin resistance partly by 
increasing adiponectin levels through transcriptional activation [97]. In addition, 
lifestyle and surgical interventions with weight loss have also led to a significant 
increase of adiponectin concentration [193, 194]. Motivated by our results in Study 
III, if a causal relationship exists between adiponectin and insulin sensitivity, dietary 
factors that affect adiponectin levels would be of interest, as already shown for coffee 
[195] and alcohol [196] in RCTs. Another viable strategy to enhance insulin 
sensitivity is to up-regulate adiponectin receptors and this includes an approach to 
develop receptor agonists that can mimic adiponectin actions. Some studies have 
reported proteins or short-peptides that could function as adiponectin receptor agonist 
[197, 198] and further research in this area is promising.  
 
Compared with currently used anti-diabetic drugs, novel drugs that may enhance the 
effect of adiponectin possess several potential advantages [21]. For example, in 
addition to its anti-diabetic and lipid-lowering effects, adiponectin also has an anti-
inflammatory property which potentially prevents atherogenesis, although this still 
need to be supported by further evidence given the association between adiponectin 
and cardiovascular disease death. Moreover, anti-diabetic drugs commonly incur 
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weight gain and adiponectin seems to avoid this. However, our findings on CDH13 in 
Study II may be a cautionary tale for drug development that not all ways to increase 
adiponectin are beneficial, especially when it concerns the vascular systems. 
 
Future research on the therapeutic potentials of adiponectin could also focus on the 
changes of metabolic profiles in relation to the presence/alteration of adiponectin, 
using a combination of genomic, transcriptomic, metabolomic and other ‘omic’ 
approaches. 
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